NCT07131722 2026-01-23
Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II
PRG Science & Technology Co., Ltd.
Phase 1/2 Not yet recruiting
PRG Science & Technology Co., Ltd.
Massachusetts Eye and Ear Infirmary